Genmab A/S
NASDAQ:GMAB · NASDAQ Global Select
-$0.12 today
Vol 1.81M · Avg 1.85M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+22.20%
Period High
$35.34
Period Low
$20.30
Latest
$25.27
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.07B
United Therapeutics Corporation
NASDAQ:UTHR
$23.41B
Royalty Pharma plc
NASDAQ:RPRX
$23.10B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Quest Diagnostics Incorporated
NYSE:DGX
$21.89B
Incyte Corporation
NASDAQ:INCY
$19.78B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$16.86B
Tenet Healthcare Corporation
NYSE:THC
$15.38B
Exelixis, Inc.
NASDAQ:EXEL
$13.18B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.91B
What is the latest GMAB filing?
The latest filing shown is 6-K dated Jun 17, 2026.
How many recent filings does GMAB have?
Intrinsic Alpha currently shows 20 recent filings for GMAB.
Explore More
Continue the stock analysis
Jump to another research area for this company.